Memantine for advanced liver cancer and cirrhosis
Part of Cancer, Digestive system clinical trials.
This trial tests if memantine, a medication typically used for memory problems, can help people with advanced liver cancer and cirrhosis. It is for those who cannot have standard aggressive treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been newly diagnosed with liver cancer (hepatocellular carcinoma) that has not been treated yet and cannot be removed with surgery.
- Your cirrhosis is moderate to severe (Child-Pugh score B7 or higher) and you are not a candidate for strong systemic treatment (like chemotherapy).
- You have adequate blood counts and organ function.
- If you are sexually active and could become pregnant or get a partner pregnant, you must agree to use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if combining two immunotherapy drugs (atezolizumab and bevacizumab) with a brain-health medicine (memantine) can help people with advanced liver cancer that isn't treatable with surgery. It aims to see if this triple therapy works better than standard options.
This trial tests a new drug called BAY 3547926 for people with advanced liver cancer that cannot be removed with surgery or has not responded to other treatments. The goal is to see if the drug is safe and how well it works.
This Phase 3 trial studies whether namodenoson can slow or control advanced hepatocellular carcinoma (liver cancer) in people whose cirrhosis is in a specific middle range. It may help if standard treatments have not worked or the cancer has spread and is not expected to be cured.
This trial tests a new medicine, PF-08634404, alone or with other treatments for adults with advanced liver cancer that cannot be removed by surgery or has spread. It is for people who have not had prior systemic therapy and have good liver function.
This trial tests a combination of two immunotherapy drugs, tremelimumab and durvalumab, for people with advanced liver cancer (HCC) who have moderate cirrhosis (Child-Pugh B). The goal is to see if this treatment can shrink tumors or slow cancer growth.
This trial tests a new drug combination called MRG006A for people with advanced liver cancer (hepatocellular carcinoma) that cannot be removed by surgery or treated with local therapies. The goal is to see if it helps shrink tumors or slow cancer growth.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.